Australia Markets close in 5 hrs 40 mins

Bellicum Pharmaceuticals, Inc. (BLCM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3171-0.0829 (-20.73%)
At close: 04:00PM EDT
0.3300 +0.01 (+4.07%)
After hours: 06:56PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.56
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 32.2000
52-week low 30.2900
50-day moving average 31.0539
200-day moving average 31.1157

Share statistics

Avg vol (3-month) 378.91k
Avg vol (10-day) 3193.21k
Shares outstanding 58.61M
Implied shares outstanding 6N/A
Float 87.06M
% held by insiders 14.41%
% held by institutions 131.48%
Shares short (30 Jan 2023) 493.78k
Short ratio (30 Jan 2023) 41.32
Short % of float (30 Jan 2023) 41.24%
Short % of shares outstanding (30 Jan 2023) 41.09%
Shares short (prior month 29 Dec 2022) 491.7k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 305 Feb 2020
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 305 Feb 2020

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,649.33%

Management effectiveness

Return on assets (ttm)-57.64%
Return on equity (ttm)-103.45%

Income statement

Revenue (ttm)1.5M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)-80.00%
Gross profit (ttm)-17.38M
EBITDA -24.72M
Net income avi to common (ttm)-16.25M
Diluted EPS (ttm)-1.3410
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)28.76M
Total cash per share (mrq)3.34
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.44
Book value per share (mrq)-0.30

Cash flow statement

Operating cash flow (ttm)-24.9M
Levered free cash flow (ttm)-22.88M